Positron emission tomography (PET) imaging of brain amyloid beta is nowclinically available in several countries including the United States andthe United Kingdom, but not Canada. It has become an established techniquein the field of neuroimaging of aging and dementia, with data incorporatedin the new consensus guidelines for the diagnosis of Alzheimer disease andpredementia Alzheimer’s disease–related conditions. At this point, there arethree US Food and Drug Administration– and European Union–approved tracers.Guided by appropriate use criteria developed in 2013 by the Alzheimer’sAssociation and the Society of Nuclear Medicine and Molecular Imaging, theutility of amyloid imaging in medical practice is now supported by a growingbody of research. In this paper, we aimed to provide an update on the 2012Canadian consensus guidelines to dementia care practitioners on proper useof amyloid imaging. We also wished to generate momentum for the industry tosubmit a new drug proposal to Health Canada. A group of local, national, andinternational dementia experts and imaging specialists met to discussscenarios in which amyloid PET could be used appropriately. Peer-reviewedand published literature between January 2004 and May 2015 was searched.Technical and regulatory considerations pertaining to Canada wereconsidered. The results of a survey of current practices in Canadiandementia centers were considered. A set of specific clinical and researchguidelines was agreed on that defines the types of patients and clinicalcircumstances in which amyloid PET could be used in Canada. Future researchdirections were also outlined, notably the importance of studies that wouldassess the pharmaco-economics of amyloid imaging.